826 related articles for article (PubMed ID: 29730603)
1. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
Zeissig S; Rosati E; Dowds CM; Aden K; Bethge J; Schulte B; Pan WH; Mishra N; Zuhayra M; Marx M; Paulsen M; Strigli A; Conrad C; Schuldt D; Sinha A; Ebsen H; Kornell SC; Nikolaus S; Arlt A; Kabelitz D; Ellrichmann M; Lützen U; Rosenstiel PC; Franke A; Schreiber S
Gut; 2019 Jan; 68(1):25-39. PubMed ID: 29730603
[TBL] [Abstract][Full Text] [Related]
2. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
[TBL] [Abstract][Full Text] [Related]
3. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
Boden EK; Shows DM; Chiorean MV; Lord JD
Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
[TBL] [Abstract][Full Text] [Related]
4. Blockade of αEβ7 integrin suppresses accumulation of CD8
Zundler S; Schillinger D; Fischer A; Atreya R; López-Posadas R; Watson A; Neufert C; Atreya I; Neurath MF
Gut; 2017 Nov; 66(11):1936-1948. PubMed ID: 27543429
[TBL] [Abstract][Full Text] [Related]
5. [Vedolizumab in the treatment of Crohn's disease].
Gisbert JP; Domènech E
Gastroenterol Hepatol; 2015 May; 38(5):338-48. PubMed ID: 25619903
[TBL] [Abstract][Full Text] [Related]
6. Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases.
Rath T; Billmeier U; Ferrazzi F; Vieth M; Ekici A; Neurath MF; Atreya R
Front Immunol; 2018; 9():1700. PubMed ID: 30131801
[TBL] [Abstract][Full Text] [Related]
7. Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis.
Veny M; Garrido-Trigo A; Corraliza AM; Masamunt MC; Bassolas-Molina H; Esteller M; Arroyes M; Tristán E; Fernández-Clotet A; Ordás I; Ricart E; Esteve M; Panés J; Salas A
J Crohns Colitis; 2021 Mar; 15(3):441-452. PubMed ID: 32926095
[TBL] [Abstract][Full Text] [Related]
8. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.
Lynch KD; Chapman RW; Keshav S; Montano-Loza AJ; Mason AL; Kremer AE; Vetter M; de Krijger M; Ponsioen CY; Trivedi P; Hirschfield G; Schramm C; Liu CH; Bowlus CL; Estes DJ; Pratt D; Hedin C; Bergquist A; de Vries AC; van der Woude CJ; Yu L; Assis DN; Boyer J; Ytting H; Hallibasic E; Trauner M; Marschall HU; Daretti LM; Marzioni M; Yimam KK; Perin N; Floreani A; Beretta-Piccoli BT; Rogers JK; ; Levy C
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):179-187.e6. PubMed ID: 31100458
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D Is Associated with α4β7+ Immunophenotypes and Predicts Vedolizumab Therapy Failure in Patients with Inflammatory Bowel Disease.
Gubatan J; Rubin SJS; Bai L; Haileselassie Y; Levitte S; Balabanis T; Patel A; Sharma A; Sinha SR; Habtezion A
J Crohns Colitis; 2021 Dec; 15(12):1980-1990. PubMed ID: 34180967
[TBL] [Abstract][Full Text] [Related]
10. Subsets of mononuclear phagocytes are enriched in the inflamed colons of patients with IBD.
Liu H; Dasgupta S; Fu Y; Bailey B; Roy C; Lightcap E; Faustin B
BMC Immunol; 2019 Nov; 20(1):42. PubMed ID: 31718550
[TBL] [Abstract][Full Text] [Related]
11. Differential Effects of Ontamalimab Versus Vedolizumab on Immune Cell Trafficking in Intestinal Inflammation and Inflammatory Bowel Disease.
Schulze LL; Becker E; Dedden M; Liu LJ; van Passen C; Mohamed-Abdou M; Müller TM; Wiendl M; Ullrich KAM; Atreya I; Leppkes M; Ekici AB; Kirchner P; Stürzl M; Sexton D; Palliser D; Atreya R; Siegmund B; ; Neurath MF; Zundler S
J Crohns Colitis; 2023 Nov; 17(11):1817-1832. PubMed ID: 37208197
[TBL] [Abstract][Full Text] [Related]
12. Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells.
Jovani M; Danese S
Curr Drug Targets; 2013 Nov; 14(12):1433-43. PubMed ID: 23980911
[TBL] [Abstract][Full Text] [Related]
13. Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases.
Coletta M; Paroni M; Alvisi MF; De Luca M; Rulli E; Mazza S; Facciotti F; Lattanzi G; Strati F; Abrignani S; Fantini MC; Vecchi M; Geginat J; Caprioli F
J Crohns Colitis; 2020 Sep; 14(9):1190-1201. PubMed ID: 32100016
[TBL] [Abstract][Full Text] [Related]
14. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.
Scribano ML
World J Gastroenterol; 2018 Jun; 24(23):2457-2467. PubMed ID: 29930467
[TBL] [Abstract][Full Text] [Related]
15. Mucosal α4β7+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis.
Roosenboom B; Wahab PJ; Smids C; Meijer J; Kemperman LGJM; Groenen MJM; van Lochem EG; Horjus Talabur Horje CS
Inflamm Bowel Dis; 2024 Jun; 30(6):930-938. PubMed ID: 37436917
[TBL] [Abstract][Full Text] [Related]
16. A product review of vedolizumab in inflammatory bowel disease.
Battat R; Dulai PS; Jairath V; Vande Casteele N
Hum Vaccin Immunother; 2019; 15(10):2482-2490. PubMed ID: 30897022
[TBL] [Abstract][Full Text] [Related]
17. Systemic Chemokine Levels with "Gut-Specific" Vedolizumab in Patients with Inflammatory Bowel Disease-A Pilot Study.
Zwicker S; Lira-Junior R; Höög C; Almer S; Boström EA
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28829369
[TBL] [Abstract][Full Text] [Related]
18. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
[TBL] [Abstract][Full Text] [Related]
19. Vedolizumab Efficacy Is Associated With Decreased Intracolonic Dendritic Cells, Not Memory T Cells.
Boden EK; Kongala R; Hindmarch DC; Shows DM; Juarez JG; Lord JD
Inflamm Bowel Dis; 2024 May; 30(5):704-717. PubMed ID: 37837660
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]